Ruijie Liu
About
Research
Publications
2025
Dual-specificity phosphatases: an update on their activity regulation and roles in metabolic diseases
De Roo C, McLean E, Liu R. Dual-specificity phosphatases: an update on their activity regulation and roles in metabolic diseases. Current Opinion In Physiology 2025, 44: 100816. DOI: 10.1016/j.cophys.2025.100816.Peer-Reviewed Original ResearchDual-specificity phosphataseProtein kinaseReversible protein phosphorylationPost-translational regulationCellular signal transductionIn vivo functionProtein phosphorylationProtein phosphatasesSerine/threonine phosphataseSignal transductionSignal terminationTyrosine phosphataseTyrosine residuesTarget proteinsActivity regulationNeurodegenerative disordersProteinEnergy metabolismSerine/threonineKinaseMetabolic diseasesPhosphataseAbnormal expressionTyrosineNonalcoholic fatty liver diseaseERK1/2 Inhibition Alleviates Diabetic Cardiomyopathy by Suppressing Fatty Acid Metabolism
McLean E, Roo C, Maag A, Coble M, Cano J, Liu R. ERK1/2 Inhibition Alleviates Diabetic Cardiomyopathy by Suppressing Fatty Acid Metabolism. Frontiers In Bioscience-Landmark 2025, 30: 26700. PMID: 39862096, DOI: 10.31083/fbl26700.Peer-Reviewed Original ResearchConceptsInhibition of ERK1/2Messenger ribonucleic acidDiabetic miceFatty acid metabolismCardiac remodelingU0126 treatmentDiabetic cardiomyopathyPolymerase chain reactionERK1/2 phosphorylationGenes associated with hypertrophyAcid metabolismPharmacological inhibition of ERK1/2Streptozotocin (STZ)-induced diabetic miceSuppressing fatty acid metabolismParaffin-embedded tissuesStreptozotocin-induced diabetic miceExtracellular signal-regulated protein kinases 1Phosphorylation of ERK1/2Masson's trichrome stainingAdministration of STZReal-time polymerase chain reactionERK1/2 phosphorylation levelsElevated phosphorylation of ERK1/2Increased fatty acid metabolismBlood glucose levels
2024
Access to treatment before and after Medicare coverage of opioid treatment programs
Liu R, Beetham T, Newton H, Busch S. Access to treatment before and after Medicare coverage of opioid treatment programs. Health Affairs Scholar 2024, 2: qxae076. PMID: 38938273, PMCID: PMC11210307, DOI: 10.1093/haschl/qxae076.Peer-Reviewed Original ResearchTreatment servicesOpioid use disorderTreatment programsOpioid treatment programsMedicare coverageFor-profit statusCounty-level changesTreat opioid use disorderNonwhite residentsNonwhite populationsOpioid use disorder treatment servicesSociodemographic characteristicsNational DirectoryServicesUse disorderTreatment facilitiesOutpatient settingMedicareAccessOpioid
Get In Touch
Contacts
Email